{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 41,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "appendix",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide highlights 5 regulatory approvals and 1 positive CHMP opinion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/32",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "HER2+ = Human epidermal growth factor receptor 2-positive; CHMP = Committee for Medicinal Products for Human Use. Collaboration partners: Daiichi Sankyo (Enhertu).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bec0e4c7-2f60-440f-b7e5-9e1e52dbfb7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.7,
        "x": 0.23,
        "y": 0.25
      },
      "kind": "list",
      "text": "5 regulatory approvals in major markets, including: Imfinzi +/- Imjudo (EU) non-small cell lung cancer (1st-line) (POSEIDON); Imfinzi + Imjudo (EU) hepatocellular carcinoma (1st-line) (HIMALAYA); Enhertu (CN) HER2+ breast cancer (2nd-line) (DESTINY-Breast03); Calquence (EU) maleate tablet formulation; Calquence (CN) mantle cell lymphoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a3ccf62-bc45-48db-9583-d6e677960cf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.23,
        "y": 0.67
      },
      "kind": "list",
      "text": "1 positive CHMP opinion: Ultomiris (EU) neuromyelitis optica spectrum disorder (CHAMPION-NMO)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55c4e8a6-2e49-4b51-a4c8-2e5d1c6e15d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Delivering on science-led innovation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "107013db-6c6b-4baa-810c-48c0b239fc2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Selected key pipeline highlights since Q4/FY 2022 results",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ede122b1-83f9-4778-b454-61d692117ac9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d12fbfa7-3848-4ef0-be77-dcbc8314417f",
      "evidence": "list/bullet: 5 regulatory approvals in major markets, including: Imfinzi +/- Imjudo (EU) non-small cell lung cancer (1st-line) (POSEIDON); Imfinzi + Imjudo (EU) hepatocellular carcinoma (1st-line) (HIMALAYA); Enhertu (CN",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}